Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hemoglobin ; 29(3): 215-9, 2005.
Article in English | MEDLINE | ID: mdl-16114185

ABSTRACT

Hb E-Saskatoon [beta22(B4)Glu-->Lys] does not cause any clinical symptoms in the heterozygous state. The homozygous state shows moderate phenotype expression. It has also been detected in association with beta-thalassemia. We present the first case of Hb E-Saskatoon associated with Hb Lepore-Baltimore. This unusual combination of mutations does not aggravate the clinical picture, as only microcytosis and hypochromia have been observed. Hb E-Saskatoon can only be correctly characterized by ion exchange high performance liquid chromatography (HPLC) or by DNA sequencing.


Subject(s)
Anemia, Hypochromic/genetics , Hemoglobin E/genetics , Hemoglobins, Abnormal/genetics , Adult , Anemia, Hypochromic/blood , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , DNA Mutational Analysis , Female , Hemoglobin E/analysis , Hemoglobins, Abnormal/analysis , Humans , Male , Middle Aged , Spain
2.
Genet Test ; 8(3): 263-7, 2004.
Article in English | MEDLINE | ID: mdl-15727249

ABSTRACT

Hereditary hemochromatosis (HH) is an autosomal recessive disease caused by a defective iron absorption. C282Y is the most frequent HFE gene mutation causing HH in Northern European populations and their descendants. However, two other mutations, H63D and S65C, have been described as pathogenic changes. In this study, we have tried to evaluate the frequency of these three mutations in our community. Eighty-three patients with clinical and/or biochemical features of hemochromatosis and 150 controls were screened for H63D, S65C, and C282Y mutations using a PCR-restriction fragment length polymorphism (RFLP)-based strategy. In contrast to previous studies, 7% of the patients were homozygous for C282Y mutation. The remaining patients were 20% H63D homozygous, 10% H63D/C282Y compound heterozygous, 1% H63D/S65C compound heterozygous, 22% H63D heterozygous, 2% C282Y heterozygous, 2% S65C heterozygous, and 36% of patients lacked any of the three mutations studied, despite the fact that they showed clinical/biochemical features of hemochromatosis. We observed a high frequency of the H63D mutation in both the control group and patients, whereas the main genotypes implicated in HH in our series were H63D homozygous and H63D/C282Y compound heterozygous. We propose that the H63D mutation be analyzed in HH patients from our geographic area. Moreover, further studies are needed to elucidate the role of this mutation in the development of HH and the genetic, environmental or other factors that affect the genotype-phenotype correlation between H63D and hemochromatosis.


Subject(s)
Gene Frequency , Hemochromatosis/genetics , Histocompatibility Antigens Class I/genetics , Membrane Proteins/genetics , Point Mutation/genetics , Female , Hemochromatosis/diagnosis , Hemochromatosis/ethnology , Hemochromatosis Protein , Heterozygote , Humans , Male , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...